nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefotaxime—SLC22A11—Conjugated Estrogens—prostate cancer	0.17	0.258	CbGbCtD
Cefotaxime—SLC22A11—Estradiol—prostate cancer	0.15	0.227	CbGbCtD
Cefotaxime—SLC22A8—Conjugated Estrogens—prostate cancer	0.0991	0.15	CbGbCtD
Cefotaxime—SLC22A8—Estradiol—prostate cancer	0.087	0.132	CbGbCtD
Cefotaxime—SLC22A7—Docetaxel—prostate cancer	0.0851	0.129	CbGbCtD
Cefotaxime—SLC22A6—Conjugated Estrogens—prostate cancer	0.069	0.105	CbGbCtD
Cefotaxime—SLC22A8—urine—prostate cancer	0.00523	0.214	CbGeAlD
Cefotaxime—SLC22A11—renal system—prostate cancer	0.00227	0.0928	CbGeAlD
Cefotaxime—SLC22A7—renal system—prostate cancer	0.00221	0.0905	CbGeAlD
Cefotaxime—SLC22A11—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00202	0.0493	CbGpPWpGaD
Cefotaxime—SLC15A1—epithelium—prostate cancer	0.00192	0.0784	CbGeAlD
Cefotaxime—SLC22A8—prostate gland—prostate cancer	0.00188	0.0768	CbGeAlD
Cefotaxime—SLC22A7—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00183	0.0447	CbGpPWpGaD
Cefotaxime—SLC15A1—renal system—prostate cancer	0.00178	0.0727	CbGeAlD
Cefotaxime—SLC22A11—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00165	0.0402	CbGpPWpGaD
Cefotaxime—SLC15A2—prostate gland—prostate cancer	0.00163	0.0667	CbGeAlD
Cefotaxime—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00154	0.0376	CbGpPWpGaD
Cefotaxime—SLC22A7—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00149	0.0365	CbGpPWpGaD
Cefotaxime—SLC22A7—testis—prostate cancer	0.00143	0.0585	CbGeAlD
Cefotaxime—SLC15A2—seminal vesicle—prostate cancer	0.00138	0.0564	CbGeAlD
Cefotaxime—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00129	0.0314	CbGpPWpGaD
Cefotaxime—SLC22A8—renal system—prostate cancer	0.00128	0.0523	CbGeAlD
Cefotaxime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00127	0.0309	CbGpPWpGaD
Cefotaxime—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00126	0.0307	CbGpPWpGaD
Cefotaxime—Cefazolin—PON1—prostate cancer	0.00123	0.485	CrCbGaD
Cefotaxime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00118	0.0287	CbGpPWpGaD
Cefotaxime—SLC15A2—renal system—prostate cancer	0.00111	0.0455	CbGeAlD
Cefotaxime—SLC15A2—urethra—prostate cancer	0.00109	0.0447	CbGeAlD
Cefotaxime—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00105	0.0256	CbGpPWpGaD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—UMPS—prostate cancer	0.000981	0.0239	CbGpPWpGaD
Cefotaxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000746	0.0182	CbGpPWpGaD
Cefotaxime—SLC15A2—testis—prostate cancer	0.000718	0.0294	CbGeAlD
Cefotaxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000692	0.0169	CbGpPWpGaD
Cefotaxime—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000628	0.0153	CbGpPWpGaD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—CYP2A6—prostate cancer	0.000594	0.0145	CbGpPWpGaD
Cefotaxime—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.00057	0.0139	CbGpPWpGaD
Cefotaxime—SLC15A2—lymph node—prostate cancer	0.000521	0.0213	CbGeAlD
Cefotaxime—Cefdinir—MPO—prostate cancer	0.000504	0.199	CrCbGaD
Cefotaxime—Cefaclor—MPO—prostate cancer	0.000499	0.197	CrCbGaD
Cefotaxime—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000479	0.0117	CbGpPWpGaD
Cefotaxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000469	0.0114	CbGpPWpGaD
Cefotaxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000469	0.0114	CbGpPWpGaD
Cefotaxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000435	0.0106	CbGpPWpGaD
Cefotaxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000435	0.0106	CbGpPWpGaD
Cefotaxime—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000405	0.00988	CbGpPWpGaD
Cefotaxime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.0004	0.00976	CbGpPWpGaD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—TYMS—prostate cancer	0.000387	0.00946	CbGpPWpGaD
Cefotaxime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000384	0.00937	CbGpPWpGaD
Cefotaxime—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000367	0.00896	CbGpPWpGaD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000361	0.00881	CbGpPWpGaD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—ERCC2—prostate cancer	0.00036	0.00879	CbGpPWpGaD
Cefotaxime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000356	0.0087	CbGpPWpGaD
Cefotaxime—Pain—Conjugated Estrogens—prostate cancer	0.000343	0.00126	CcSEcCtD
Cefotaxime—Vaginal infection—Doxorubicin—prostate cancer	0.000341	0.00125	CcSEcCtD
Cefotaxime—Ill-defined disorder—Mitoxantrone—prostate cancer	0.00034	0.00125	CcSEcCtD
Cefotaxime—Neutropenia—Docetaxel—prostate cancer	0.00034	0.00125	CcSEcCtD
Cefotaxime—Aplastic anaemia—Doxorubicin—prostate cancer	0.000339	0.00125	CcSEcCtD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—MTHFR—prostate cancer	0.000338	0.00826	CbGpPWpGaD
Cefotaxime—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000336	0.00124	CcSEcCtD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000333	0.00814	CbGpPWpGaD
Cefotaxime—Feeling abnormal—Goserelin—prostate cancer	0.000333	0.00123	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Goserelin—prostate cancer	0.000331	0.00122	CcSEcCtD
Cefotaxime—Erythema multiforme—Etoposide—prostate cancer	0.000331	0.00122	CcSEcCtD
Cefotaxime—Discomfort—Estradiol—prostate cancer	0.00033	0.00122	CcSEcCtD
Cefotaxime—Malaise—Mitoxantrone—prostate cancer	0.00033	0.00121	CcSEcCtD
Cefotaxime—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.00033	0.00805	CbGpPWpGaD
Cefotaxime—Neutropenia—Capecitabine—prostate cancer	0.000329	0.00121	CcSEcCtD
Cefotaxime—Leukopenia—Mitoxantrone—prostate cancer	0.000328	0.00121	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000328	0.00121	CcSEcCtD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000327	0.008	CbGpPWpGaD
Cefotaxime—Hepatic function abnormal—Epirubicin—prostate cancer	0.000324	0.00119	CcSEcCtD
Cefotaxime—Urticaria—Goserelin—prostate cancer	0.000321	0.00118	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000321	0.00118	CcSEcCtD
Cefotaxime—Anaphylactic shock—Estradiol—prostate cancer	0.000321	0.00118	CcSEcCtD
Cefotaxime—Abdominal pain—Goserelin—prostate cancer	0.00032	0.00118	CcSEcCtD
Cefotaxime—Body temperature increased—Goserelin—prostate cancer	0.00032	0.00118	CcSEcCtD
Cefotaxime—Renal failure—Docetaxel—prostate cancer	0.000318	0.00117	CcSEcCtD
Cefotaxime—Urticaria—Conjugated Estrogens—prostate cancer	0.000318	0.00117	CcSEcCtD
Cefotaxime—Convulsion—Mitoxantrone—prostate cancer	0.000317	0.00117	CcSEcCtD
Cefotaxime—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000317	0.00117	CcSEcCtD
Cefotaxime—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000317	0.00117	CcSEcCtD
Cefotaxime—Jaundice—Docetaxel—prostate cancer	0.000316	0.00116	CcSEcCtD
Cefotaxime—Shock—Estradiol—prostate cancer	0.000315	0.00116	CcSEcCtD
Cefotaxime—Vomiting—Ethinyl Estradiol—prostate cancer	0.000312	0.00115	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000311	0.00114	CcSEcCtD
Cefotaxime—Rash—Ethinyl Estradiol—prostate cancer	0.00031	0.00114	CcSEcCtD
Cefotaxime—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00031	0.00114	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000309	0.00756	CbGpPWpGaD
Cefotaxime—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000309	0.00753	CbGpPWpGaD
Cefotaxime—Renal failure—Capecitabine—prostate cancer	0.000308	0.00113	CcSEcCtD
Cefotaxime—Discomfort—Mitoxantrone—prostate cancer	0.000308	0.00113	CcSEcCtD
Cefotaxime—Headache—Ethinyl Estradiol—prostate cancer	0.000308	0.00113	CcSEcCtD
Cefotaxime—Jaundice—Capecitabine—prostate cancer	0.000306	0.00112	CcSEcCtD
Cefotaxime—Agranulocytosis—Docetaxel—prostate cancer	0.000302	0.00111	CcSEcCtD
Cefotaxime—Hepatic function abnormal—Doxorubicin—prostate cancer	0.0003	0.0011	CcSEcCtD
Cefotaxime—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000299	0.00731	CbGpPWpGaD
Cefotaxime—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000299	0.0011	CcSEcCtD
Cefotaxime—Hypersensitivity—Goserelin—prostate cancer	0.000298	0.0011	CcSEcCtD
Cefotaxime—Renal impairment—Epirubicin—prostate cancer	0.000298	0.0011	CcSEcCtD
Cefotaxime—Dermatitis bullous—Epirubicin—prostate cancer	0.000297	0.00109	CcSEcCtD
Cefotaxime—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000295	0.00109	CcSEcCtD
Cefotaxime—Shock—Mitoxantrone—prostate cancer	0.000294	0.00108	CcSEcCtD
Cefotaxime—Neutropenia—Prednisone—prostate cancer	0.000293	0.00108	CcSEcCtD
Cefotaxime—Agranulocytosis—Capecitabine—prostate cancer	0.000293	0.00108	CcSEcCtD
Cefotaxime—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000293	0.00108	CcSEcCtD
Cefotaxime—Haemoglobin—Docetaxel—prostate cancer	0.000292	0.00107	CcSEcCtD
Cefotaxime—Nausea—Ethinyl Estradiol—prostate cancer	0.000292	0.00107	CcSEcCtD
Cefotaxime—Haemorrhage—Docetaxel—prostate cancer	0.000291	0.00107	CcSEcCtD
Cefotaxime—Hepatitis—Docetaxel—prostate cancer	0.000291	0.00107	CcSEcCtD
Cefotaxime—Pruritus—Goserelin—prostate cancer	0.000286	0.00105	CcSEcCtD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000285	0.00697	CbGpPWpGaD
Cefotaxime—Pruritus—Conjugated Estrogens—prostate cancer	0.000283	0.00104	CcSEcCtD
Cefotaxime—Haemoglobin—Capecitabine—prostate cancer	0.000283	0.00104	CcSEcCtD
Cefotaxime—Ill-defined disorder—Etoposide—prostate cancer	0.000283	0.00104	CcSEcCtD
Cefotaxime—Hepatitis—Capecitabine—prostate cancer	0.000281	0.00104	CcSEcCtD
Cefotaxime—Haemorrhage—Capecitabine—prostate cancer	0.000281	0.00104	CcSEcCtD
Cefotaxime—Diarrhoea—Goserelin—prostate cancer	0.000277	0.00102	CcSEcCtD
Cefotaxime—Renal impairment—Doxorubicin—prostate cancer	0.000276	0.00101	CcSEcCtD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000275	0.00672	CbGpPWpGaD
Cefotaxime—Erythema multiforme—Docetaxel—prostate cancer	0.000275	0.00101	CcSEcCtD
Cefotaxime—Malaise—Etoposide—prostate cancer	0.000275	0.00101	CcSEcCtD
Cefotaxime—Dermatitis bullous—Doxorubicin—prostate cancer	0.000274	0.00101	CcSEcCtD
Cefotaxime—Pain—Estradiol—prostate cancer	0.000274	0.00101	CcSEcCtD
Cefotaxime—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000274	0.00101	CcSEcCtD
Cefotaxime—Leukopenia—Etoposide—prostate cancer	0.000273	0.001	CcSEcCtD
Cefotaxime—Erythema multiforme—Capecitabine—prostate cancer	0.000266	0.000979	CcSEcCtD
Cefotaxime—Feeling abnormal—Estradiol—prostate cancer	0.000264	0.000972	CcSEcCtD
Cefotaxime—Convulsion—Etoposide—prostate cancer	0.000264	0.00097	CcSEcCtD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000264	0.00644	CbGpPWpGaD
Cefotaxime—Gastrointestinal pain—Estradiol—prostate cancer	0.000262	0.000965	CcSEcCtD
Cefotaxime—Arrhythmia—Docetaxel—prostate cancer	0.00026	0.000955	CcSEcCtD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000259	0.00632	CbGpPWpGaD
Cefotaxime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000257	0.00629	CbGpPWpGaD
Cefotaxime—Vomiting—Goserelin—prostate cancer	0.000257	0.000946	CcSEcCtD
Cefotaxime—Discomfort—Etoposide—prostate cancer	0.000256	0.000942	CcSEcCtD
Cefotaxime—Pain—Mitoxantrone—prostate cancer	0.000256	0.00094	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000255	0.000939	CcSEcCtD
Cefotaxime—Rash—Goserelin—prostate cancer	0.000255	0.000938	CcSEcCtD
Cefotaxime—Dermatitis—Goserelin—prostate cancer	0.000255	0.000937	CcSEcCtD
Cefotaxime—Vomiting—Conjugated Estrogens—prostate cancer	0.000255	0.000937	CcSEcCtD
Cefotaxime—Urticaria—Estradiol—prostate cancer	0.000255	0.000937	CcSEcCtD
Cefotaxime—Body temperature increased—Estradiol—prostate cancer	0.000253	0.000932	CcSEcCtD
Cefotaxime—Abdominal pain—Estradiol—prostate cancer	0.000253	0.000932	CcSEcCtD
Cefotaxime—Headache—Goserelin—prostate cancer	0.000253	0.000932	CcSEcCtD
Cefotaxime—Rash—Conjugated Estrogens—prostate cancer	0.000253	0.000929	CcSEcCtD
Cefotaxime—Dermatitis—Conjugated Estrogens—prostate cancer	0.000252	0.000928	CcSEcCtD
Cefotaxime—Haemoglobin—Prednisone—prostate cancer	0.000252	0.000927	CcSEcCtD
Cefotaxime—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000252	0.00614	CbGpPWpGaD
Cefotaxime—Arrhythmia—Capecitabine—prostate cancer	0.000251	0.000925	CcSEcCtD
Cefotaxime—Headache—Conjugated Estrogens—prostate cancer	0.000251	0.000923	CcSEcCtD
Cefotaxime—Haemorrhage—Prednisone—prostate cancer	0.000251	0.000922	CcSEcCtD
Cefotaxime—Anaphylactic shock—Etoposide—prostate cancer	0.000249	0.000914	CcSEcCtD
Cefotaxime—Feeling abnormal—Mitoxantrone—prostate cancer	0.000246	0.000906	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000245	0.00597	CbGpPWpGaD
Cefotaxime—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000244	0.000899	CcSEcCtD
Cefotaxime—Thrombocytopenia—Etoposide—prostate cancer	0.000243	0.000895	CcSEcCtD
Cefotaxime—Eosinophilia—Epirubicin—prostate cancer	0.000243	0.000892	CcSEcCtD
Cefotaxime—Nausea—Goserelin—prostate cancer	0.00024	0.000884	CcSEcCtD
Cefotaxime—Nausea—Conjugated Estrogens—prostate cancer	0.000238	0.000875	CcSEcCtD
Cefotaxime—Urticaria—Mitoxantrone—prostate cancer	0.000237	0.000873	CcSEcCtD
Cefotaxime—Hypersensitivity—Estradiol—prostate cancer	0.000236	0.000869	CcSEcCtD
Cefotaxime—Body temperature increased—Mitoxantrone—prostate cancer	0.000236	0.000869	CcSEcCtD
Cefotaxime—Abdominal pain—Mitoxantrone—prostate cancer	0.000236	0.000869	CcSEcCtD
Cefotaxime—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000236	0.000869	CcSEcCtD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00023	0.00561	CbGpPWpGaD
Cefotaxime—Neutropenia—Epirubicin—prostate cancer	0.000229	0.000843	CcSEcCtD
Cefotaxime—Ill-defined disorder—Capecitabine—prostate cancer	0.000227	0.000836	CcSEcCtD
Cefotaxime—Pruritus—Estradiol—prostate cancer	0.000227	0.000834	CcSEcCtD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000227	0.00553	CbGpPWpGaD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000227	0.00553	CbGpPWpGaD
Cefotaxime—Leukopenia—Docetaxel—prostate cancer	0.000227	0.000833	CcSEcCtD
Cefotaxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000226	0.00552	CbGpPWpGaD
Cefotaxime—Eosinophilia—Doxorubicin—prostate cancer	0.000224	0.000826	CcSEcCtD
Cefotaxime—Arrhythmia—Prednisone—prostate cancer	0.000224	0.000824	CcSEcCtD
Cefotaxime—Malaise—Capecitabine—prostate cancer	0.000221	0.000813	CcSEcCtD
Cefotaxime—Hypersensitivity—Mitoxantrone—prostate cancer	0.00022	0.00081	CcSEcCtD
Cefotaxime—Diarrhoea—Estradiol—prostate cancer	0.000219	0.000807	CcSEcCtD
Cefotaxime—Leukopenia—Capecitabine—prostate cancer	0.000219	0.000807	CcSEcCtD
Cefotaxime—Convulsion—Docetaxel—prostate cancer	0.000219	0.000807	CcSEcCtD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000218	0.00531	CbGpPWpGaD
Cefotaxime—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000217	0.000797	CcSEcCtD
Cefotaxime—Renal failure—Epirubicin—prostate cancer	0.000215	0.00079	CcSEcCtD
Cefotaxime—Jaundice—Epirubicin—prostate cancer	0.000213	0.000783	CcSEcCtD
Cefotaxime—Pain—Etoposide—prostate cancer	0.000213	0.000782	CcSEcCtD
Cefotaxime—Neutropenia—Doxorubicin—prostate cancer	0.000212	0.00078	CcSEcCtD
Cefotaxime—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.00021	0.00513	CbGpPWpGaD
Cefotaxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.00021	0.00512	CbGpPWpGaD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000209	0.00511	CbGpPWpGaD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000209	0.00511	CbGpPWpGaD
Cefotaxime—Anaphylactic shock—Docetaxel—prostate cancer	0.000207	0.00076	CcSEcCtD
Cefotaxime—Discomfort—Capecitabine—prostate cancer	0.000206	0.000758	CcSEcCtD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000206	0.00502	CbGpPWpGaD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000206	0.00502	CbGpPWpGaD
Cefotaxime—Feeling abnormal—Etoposide—prostate cancer	0.000205	0.000753	CcSEcCtD
Cefotaxime—Diarrhoea—Mitoxantrone—prostate cancer	0.000204	0.000752	CcSEcCtD
Cefotaxime—Vomiting—Estradiol—prostate cancer	0.000204	0.00075	CcSEcCtD
Cefotaxime—Agranulocytosis—Epirubicin—prostate cancer	0.000204	0.00075	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Etoposide—prostate cancer	0.000203	0.000748	CcSEcCtD
Cefotaxime—Shock—Docetaxel—prostate cancer	0.000203	0.000747	CcSEcCtD
Cefotaxime—Ill-defined disorder—Prednisone—prostate cancer	0.000203	0.000745	CcSEcCtD
Cefotaxime—Thrombocytopenia—Docetaxel—prostate cancer	0.000202	0.000744	CcSEcCtD
Cefotaxime—Rash—Estradiol—prostate cancer	0.000202	0.000744	CcSEcCtD
Cefotaxime—Dermatitis—Estradiol—prostate cancer	0.000202	0.000743	CcSEcCtD
Cefotaxime—Headache—Estradiol—prostate cancer	0.000201	0.000739	CcSEcCtD
Cefotaxime—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.0002	0.000737	CcSEcCtD
Cefotaxime—Angioedema—Prednisone—prostate cancer	0.000199	0.000734	CcSEcCtD
Cefotaxime—Renal failure—Doxorubicin—prostate cancer	0.000199	0.000731	CcSEcCtD
Cefotaxime—Urticaria—Etoposide—prostate cancer	0.000197	0.000726	CcSEcCtD
Cefotaxime—Haemoglobin—Epirubicin—prostate cancer	0.000197	0.000725	CcSEcCtD
Cefotaxime—Jaundice—Doxorubicin—prostate cancer	0.000197	0.000725	CcSEcCtD
Cefotaxime—Malaise—Prednisone—prostate cancer	0.000197	0.000724	CcSEcCtD
Cefotaxime—Shock—Capecitabine—prostate cancer	0.000197	0.000724	CcSEcCtD
Cefotaxime—Abdominal pain—Etoposide—prostate cancer	0.000196	0.000723	CcSEcCtD
Cefotaxime—Body temperature increased—Etoposide—prostate cancer	0.000196	0.000723	CcSEcCtD
Cefotaxime—Haemorrhage—Epirubicin—prostate cancer	0.000196	0.000721	CcSEcCtD
Cefotaxime—Hepatitis—Epirubicin—prostate cancer	0.000196	0.000721	CcSEcCtD
Cefotaxime—Thrombocytopenia—Capecitabine—prostate cancer	0.000196	0.00072	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000194	0.00475	CbGpPWpGaD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000194	0.00475	CbGpPWpGaD
Cefotaxime—Nausea—Estradiol—prostate cancer	0.00019	0.000701	CcSEcCtD
Cefotaxime—Vomiting—Mitoxantrone—prostate cancer	0.00019	0.000699	CcSEcCtD
Cefotaxime—Convulsion—Prednisone—prostate cancer	0.000189	0.000696	CcSEcCtD
Cefotaxime—Agranulocytosis—Doxorubicin—prostate cancer	0.000189	0.000694	CcSEcCtD
Cefotaxime—Rash—Mitoxantrone—prostate cancer	0.000188	0.000693	CcSEcCtD
Cefotaxime—Dermatitis—Mitoxantrone—prostate cancer	0.000188	0.000692	CcSEcCtD
Cefotaxime—Headache—Mitoxantrone—prostate cancer	0.000187	0.000688	CcSEcCtD
Cefotaxime—Erythema multiforme—Epirubicin—prostate cancer	0.000185	0.000682	CcSEcCtD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000184	0.00449	CbGpPWpGaD
Cefotaxime—Discomfort—Prednisone—prostate cancer	0.000184	0.000675	CcSEcCtD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000183	0.00448	CbGpPWpGaD
Cefotaxime—Cefradine—CYP3A4—prostate cancer	0.000183	0.0723	CrCbGaD
Cefotaxime—Hypersensitivity—Etoposide—prostate cancer	0.000183	0.000674	CcSEcCtD
Cefotaxime—Haemoglobin—Doxorubicin—prostate cancer	0.000182	0.000671	CcSEcCtD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000182	0.00443	CbGpPWpGaD
Cefotaxime—Hepatitis—Doxorubicin—prostate cancer	0.000181	0.000667	CcSEcCtD
Cefotaxime—Haemorrhage—Doxorubicin—prostate cancer	0.000181	0.000667	CcSEcCtD
Cefotaxime—Anaphylactic shock—Prednisone—prostate cancer	0.000178	0.000655	CcSEcCtD
Cefotaxime—Nausea—Mitoxantrone—prostate cancer	0.000177	0.000653	CcSEcCtD
Cefotaxime—Pain—Docetaxel—prostate cancer	0.000177	0.00065	CcSEcCtD
Cefotaxime—Pruritus—Etoposide—prostate cancer	0.000176	0.000647	CcSEcCtD
Cefotaxime—Shock—Prednisone—prostate cancer	0.000175	0.000645	CcSEcCtD
Cefotaxime—Arrhythmia—Epirubicin—prostate cancer	0.000175	0.000644	CcSEcCtD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000173	0.00422	CbGpPWpGaD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000173	0.00422	CbGpPWpGaD
Cefotaxime—Erythema multiforme—Doxorubicin—prostate cancer	0.000172	0.000631	CcSEcCtD
Cefotaxime—Pain—Capecitabine—prostate cancer	0.000171	0.000629	CcSEcCtD
Cefotaxime—Feeling abnormal—Docetaxel—prostate cancer	0.00017	0.000626	CcSEcCtD
Cefotaxime—Diarrhoea—Etoposide—prostate cancer	0.00017	0.000625	CcSEcCtD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00017	0.00415	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000169	0.00414	CbGpPWpGaD
Cefotaxime—Gastrointestinal pain—Docetaxel—prostate cancer	0.000169	0.000621	CcSEcCtD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000167	0.00407	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000166	0.00406	CbGpPWpGaD
Cefotaxime—Feeling abnormal—Capecitabine—prostate cancer	0.000165	0.000606	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Capecitabine—prostate cancer	0.000164	0.000601	CcSEcCtD
Cefotaxime—Body temperature increased—Docetaxel—prostate cancer	0.000163	0.000601	CcSEcCtD
Cefotaxime—Abdominal pain—Docetaxel—prostate cancer	0.000163	0.000601	CcSEcCtD
Cefotaxime—Arrhythmia—Doxorubicin—prostate cancer	0.000162	0.000596	CcSEcCtD
Cefotaxime—Urticaria—Capecitabine—prostate cancer	0.000159	0.000584	CcSEcCtD
Cefotaxime—Ill-defined disorder—Epirubicin—prostate cancer	0.000158	0.000583	CcSEcCtD
Cefotaxime—Abdominal pain—Capecitabine—prostate cancer	0.000158	0.000581	CcSEcCtD
Cefotaxime—Body temperature increased—Capecitabine—prostate cancer	0.000158	0.000581	CcSEcCtD
Cefotaxime—Vomiting—Etoposide—prostate cancer	0.000158	0.000581	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000158	0.00385	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000157	0.00384	CbGpPWpGaD
Cefotaxime—Rash—Etoposide—prostate cancer	0.000157	0.000576	CcSEcCtD
Cefotaxime—Dermatitis—Etoposide—prostate cancer	0.000157	0.000576	CcSEcCtD
Cefotaxime—Headache—Etoposide—prostate cancer	0.000156	0.000573	CcSEcCtD
Cefotaxime—Malaise—Epirubicin—prostate cancer	0.000154	0.000566	CcSEcCtD
Cefotaxime—Leukopenia—Epirubicin—prostate cancer	0.000153	0.000562	CcSEcCtD
Cefotaxime—Hypersensitivity—Docetaxel—prostate cancer	0.000152	0.00056	CcSEcCtD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.00015	0.00366	CbGpPWpGaD
Cefotaxime—Convulsion—Epirubicin—prostate cancer	0.000148	0.000544	CcSEcCtD
Cefotaxime—Nausea—Etoposide—prostate cancer	0.000148	0.000543	CcSEcCtD
Cefotaxime—Hypersensitivity—Capecitabine—prostate cancer	0.000147	0.000542	CcSEcCtD
Cefotaxime—Feeling abnormal—Prednisone—prostate cancer	0.000147	0.00054	CcSEcCtD
Cefotaxime—Ill-defined disorder—Doxorubicin—prostate cancer	0.000147	0.000539	CcSEcCtD
Cefotaxime—Pruritus—Docetaxel—prostate cancer	0.000146	0.000537	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Prednisone—prostate cancer	0.000146	0.000536	CcSEcCtD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000145	0.00354	CbGpPWpGaD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000144	0.00352	CbGpPWpGaD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000144	0.00352	CbGpPWpGaD
Cefotaxime—Discomfort—Epirubicin—prostate cancer	0.000144	0.000528	CcSEcCtD
Cefotaxime—Malaise—Doxorubicin—prostate cancer	0.000142	0.000524	CcSEcCtD
Cefotaxime—Urticaria—Prednisone—prostate cancer	0.000142	0.00052	CcSEcCtD
Cefotaxime—Pruritus—Capecitabine—prostate cancer	0.000141	0.00052	CcSEcCtD
Cefotaxime—Leukopenia—Doxorubicin—prostate cancer	0.000141	0.00052	CcSEcCtD
Cefotaxime—Diarrhoea—Docetaxel—prostate cancer	0.000141	0.00052	CcSEcCtD
Cefotaxime—Body temperature increased—Prednisone—prostate cancer	0.000141	0.000518	CcSEcCtD
Cefotaxime—Abdominal pain—Prednisone—prostate cancer	0.000141	0.000518	CcSEcCtD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00014	0.00342	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00014	0.00342	CbGpPWpGaD
Cefotaxime—Anaphylactic shock—Epirubicin—prostate cancer	0.000139	0.000512	CcSEcCtD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000138	0.00338	CbGpPWpGaD
Cefotaxime—Shock—Epirubicin—prostate cancer	0.000137	0.000504	CcSEcCtD
Cefotaxime—Convulsion—Doxorubicin—prostate cancer	0.000137	0.000503	CcSEcCtD
Cefotaxime—Diarrhoea—Capecitabine—prostate cancer	0.000137	0.000503	CcSEcCtD
Cefotaxime—Thrombocytopenia—Epirubicin—prostate cancer	0.000136	0.000502	CcSEcCtD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000136	0.00332	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000134	0.00327	CbGpPWpGaD
Cefotaxime—Discomfort—Doxorubicin—prostate cancer	0.000133	0.000489	CcSEcCtD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000132	0.00321	CbGpPWpGaD
Cefotaxime—Vomiting—Docetaxel—prostate cancer	0.000131	0.000483	CcSEcCtD
Cefotaxime—Hypersensitivity—Prednisone—prostate cancer	0.000131	0.000483	CcSEcCtD
Cefotaxime—Rash—Docetaxel—prostate cancer	0.00013	0.000479	CcSEcCtD
Cefotaxime—Dermatitis—Docetaxel—prostate cancer	0.00013	0.000479	CcSEcCtD
Cefotaxime—Headache—Docetaxel—prostate cancer	0.000129	0.000476	CcSEcCtD
Cefotaxime—Anaphylactic shock—Doxorubicin—prostate cancer	0.000129	0.000474	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000128	0.00314	CbGpPWpGaD
Cefotaxime—SLC22A7—Fluoropyrimidine Activity—TP53—prostate cancer	0.000128	0.00314	CbGpPWpGaD
Cefotaxime—Vomiting—Capecitabine—prostate cancer	0.000127	0.000468	CcSEcCtD
Cefotaxime—Shock—Doxorubicin—prostate cancer	0.000127	0.000466	CcSEcCtD
Cefotaxime—Thrombocytopenia—Doxorubicin—prostate cancer	0.000126	0.000464	CcSEcCtD
Cefotaxime—Rash—Capecitabine—prostate cancer	0.000126	0.000464	CcSEcCtD
Cefotaxime—Pruritus—Prednisone—prostate cancer	0.000126	0.000464	CcSEcCtD
Cefotaxime—Dermatitis—Capecitabine—prostate cancer	0.000126	0.000463	CcSEcCtD
Cefotaxime—Headache—Capecitabine—prostate cancer	0.000125	0.000461	CcSEcCtD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000124	0.00304	CbGpPWpGaD
Cefotaxime—Nausea—Docetaxel—prostate cancer	0.000123	0.000451	CcSEcCtD
Cefotaxime—Diarrhoea—Prednisone—prostate cancer	0.000122	0.000448	CcSEcCtD
Cefotaxime—Pain—Epirubicin—prostate cancer	0.000119	0.000438	CcSEcCtD
Cefotaxime—Nausea—Capecitabine—prostate cancer	0.000119	0.000437	CcSEcCtD
Cefotaxime—Cephalexin—CYP3A4—prostate cancer	0.000119	0.0467	CrCbGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000118	0.00289	CbGpPWpGaD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000117	0.00286	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000117	0.00285	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000115	0.00281	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000115	0.00281	CbGpPWpGaD
Cefotaxime—Feeling abnormal—Epirubicin—prostate cancer	0.000115	0.000422	CcSEcCtD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000114	0.00279	CbGpPWpGaD
Cefotaxime—Gastrointestinal pain—Epirubicin—prostate cancer	0.000114	0.000419	CcSEcCtD
Cefotaxime—Vomiting—Prednisone—prostate cancer	0.000113	0.000417	CcSEcCtD
Cefotaxime—Rash—Prednisone—prostate cancer	0.000112	0.000413	CcSEcCtD
Cefotaxime—Dermatitis—Prednisone—prostate cancer	0.000112	0.000413	CcSEcCtD
Cefotaxime—Headache—Prednisone—prostate cancer	0.000112	0.00041	CcSEcCtD
Cefotaxime—Urticaria—Epirubicin—prostate cancer	0.000111	0.000407	CcSEcCtD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000111	0.0027	CbGpPWpGaD
Cefotaxime—Pain—Doxorubicin—prostate cancer	0.00011	0.000405	CcSEcCtD
Cefotaxime—Abdominal pain—Epirubicin—prostate cancer	0.00011	0.000405	CcSEcCtD
Cefotaxime—Body temperature increased—Epirubicin—prostate cancer	0.00011	0.000405	CcSEcCtD
Cefotaxime—SLC22A11—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000109	0.00267	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000109	0.00267	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000107	0.00262	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000106	0.0026	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000106	0.0026	CbGpPWpGaD
Cefotaxime—Feeling abnormal—Doxorubicin—prostate cancer	0.000106	0.000391	CcSEcCtD
Cefotaxime—Nausea—Prednisone—prostate cancer	0.000106	0.000389	CcSEcCtD
Cefotaxime—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000105	0.000388	CcSEcCtD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000104	0.00255	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000104	0.00255	CbGpPWpGaD
Cefotaxime—Hypersensitivity—Epirubicin—prostate cancer	0.000103	0.000378	CcSEcCtD
Cefotaxime—Urticaria—Doxorubicin—prostate cancer	0.000102	0.000377	CcSEcCtD
Cefotaxime—Body temperature increased—Doxorubicin—prostate cancer	0.000102	0.000375	CcSEcCtD
Cefotaxime—Abdominal pain—Doxorubicin—prostate cancer	0.000102	0.000375	CcSEcCtD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000101	0.00247	CbGpPWpGaD
Cefotaxime—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000101	0.00247	CbGpPWpGaD
Cefotaxime—SLC22A7—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	9.92e-05	0.00242	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	9.87e-05	0.00241	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	9.87e-05	0.00241	CbGpPWpGaD
Cefotaxime—Pruritus—Epirubicin—prostate cancer	9.86e-05	0.000363	CcSEcCtD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	9.54e-05	0.00233	CbGpPWpGaD
Cefotaxime—Diarrhoea—Epirubicin—prostate cancer	9.53e-05	0.000351	CcSEcCtD
Cefotaxime—Hypersensitivity—Doxorubicin—prostate cancer	9.5e-05	0.000349	CcSEcCtD
Cefotaxime—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	9.37e-05	0.00229	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC22A3—prostate cancer	9.34e-05	0.00228	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC39A1—prostate cancer	9.23e-05	0.00225	CbGpPWpGaD
Cefotaxime—Pruritus—Doxorubicin—prostate cancer	9.12e-05	0.000335	CcSEcCtD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—CYP7B1—prostate cancer	9.01e-05	0.0022	CbGpPWpGaD
Cefotaxime—Vomiting—Epirubicin—prostate cancer	8.86e-05	0.000326	CcSEcCtD
Cefotaxime—Diarrhoea—Doxorubicin—prostate cancer	8.82e-05	0.000324	CcSEcCtD
Cefotaxime—Rash—Epirubicin—prostate cancer	8.78e-05	0.000323	CcSEcCtD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC26A4—prostate cancer	8.78e-05	0.00214	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC12A2—prostate cancer	8.78e-05	0.00214	CbGpPWpGaD
Cefotaxime—Dermatitis—Epirubicin—prostate cancer	8.78e-05	0.000323	CcSEcCtD
Cefotaxime—Headache—Epirubicin—prostate cancer	8.73e-05	0.000321	CcSEcCtD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	8.63e-05	0.00211	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—ABCG5—prostate cancer	8.62e-05	0.00211	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC22A3—prostate cancer	8.48e-05	0.00207	CbGpPWpGaD
Cefotaxime—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	8.34e-05	0.00204	CbGpPWpGaD
Cefotaxime—Nausea—Epirubicin—prostate cancer	8.27e-05	0.000304	CcSEcCtD
Cefotaxime—Vomiting—Doxorubicin—prostate cancer	8.2e-05	0.000301	CcSEcCtD
Cefotaxime—Rash—Doxorubicin—prostate cancer	8.13e-05	0.000299	CcSEcCtD
Cefotaxime—Dermatitis—Doxorubicin—prostate cancer	8.12e-05	0.000299	CcSEcCtD
Cefotaxime—Headache—Doxorubicin—prostate cancer	8.08e-05	0.000297	CcSEcCtD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	8.01e-05	0.00196	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.96e-05	0.00195	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.82e-05	0.00191	CbGpPWpGaD
Cefotaxime—Nausea—Doxorubicin—prostate cancer	7.66e-05	0.000282	CcSEcCtD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC22A1—prostate cancer	7.61e-05	0.00186	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—CYP7B1—prostate cancer	7.52e-05	0.00184	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.39e-05	0.00181	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC12A2—prostate cancer	7.33e-05	0.00179	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC26A4—prostate cancer	7.33e-05	0.00179	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—GNG5—prostate cancer	7.24e-05	0.00177	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC22A3—prostate cancer	7.12e-05	0.00174	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	7.04e-05	0.00172	CbGpPWpGaD
Cefotaxime—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	6.96e-05	0.0017	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC22A1—prostate cancer	6.91e-05	0.00169	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	6.69e-05	0.00163	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—ABCG5—prostate cancer	6.57e-05	0.00161	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—GNG5—prostate cancer	6.57e-05	0.0016	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	6.53e-05	0.00159	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	6.21e-05	0.00152	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—PRKACB—prostate cancer	6.17e-05	0.00151	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC22A3—prostate cancer	5.95e-05	0.00145	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.82e-05	0.00142	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC22A1—prostate cancer	5.81e-05	0.00142	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.7e-05	0.00139	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.6e-05	0.00137	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.56e-05	0.00136	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—GNG5—prostate cancer	5.52e-05	0.00135	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.49e-05	0.00134	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.38e-05	0.00131	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.29e-05	0.00129	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.28e-05	0.00129	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.13e-05	0.00125	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.04e-05	0.00123	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	4.99e-05	0.00122	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.91e-05	0.0012	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.85e-05	0.00118	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	4.76e-05	0.00116	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—PRKACB—prostate cancer	4.71e-05	0.00115	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—RXRA—prostate cancer	4.67e-05	0.00114	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—GNG5—prostate cancer	4.61e-05	0.00113	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.53e-05	0.00111	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.45e-05	0.00109	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—NCOA2—prostate cancer	4.44e-05	0.00108	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	4.31e-05	0.00105	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—SLC5A5—prostate cancer	4.24e-05	0.00103	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—RXRA—prostate cancer	4.24e-05	0.00103	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.21e-05	0.00103	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	4e-05	0.000977	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.93e-05	0.00096	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.74e-05	0.000914	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.71e-05	0.000905	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—PPARA—prostate cancer	3.57e-05	0.000871	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—RXRA—prostate cancer	3.56e-05	0.000869	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.54e-05	0.000863	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	3.29e-05	0.000804	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—PPARA—prostate cancer	3.24e-05	0.00079	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.12e-05	0.000763	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	3.06e-05	0.000747	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—RXRA—prostate cancer	2.97e-05	0.000725	CbGpPWpGaD
Cefotaxime—SLC22A11—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.83e-05	0.000691	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—PPARA—prostate cancer	2.72e-05	0.000664	CbGpPWpGaD
Cefotaxime—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.62e-05	0.000639	CbGpPWpGaD
Cefotaxime—SLC22A7—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.57e-05	0.000627	CbGpPWpGaD
Cefotaxime—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.43e-05	0.000593	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—PPARA—prostate cancer	2.27e-05	0.000554	CbGpPWpGaD
Cefotaxime—SLC22A8—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.16e-05	0.000527	CbGpPWpGaD
Cefotaxime—SLC22A6—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.8e-05	0.00044	CbGpPWpGaD
